These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 9474184

  • 1. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
    Rabbani F, Goldenberg SL, Klotz LH.
    J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
    [Abstract] [Full Text] [Related]

  • 2. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.
    Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, Chin J, Laplante S.
    Urology; 1999 Apr; 53(4):757-63. PubMed ID: 10197852
    [Abstract] [Full Text] [Related]

  • 3. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [Abstract] [Full Text] [Related]

  • 4. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
    Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.
    Urology; 2000 Aug 01; 56(2):289-94. PubMed ID: 10925096
    [Abstract] [Full Text] [Related]

  • 5. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H.
    J Urol; 2000 Jan 01; 163(1):174-8. PubMed ID: 10604340
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant hormone therapy: the Canadian trials.
    Klotz L, Gleave M, Goldenberg SL.
    Mol Urol; 2000 Jan 01; 4(3):233-7;discussion 239. PubMed ID: 11062379
    [Abstract] [Full Text] [Related]

  • 7. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, Canadian Uro-Oncology Group.
    J Urol; 2001 Aug 01; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [Abstract] [Full Text] [Related]

  • 8. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
    Rabbani F, Perrotti M, Bastar A, Fair WR.
    J Urol; 1999 Mar 01; 161(3):847-52. PubMed ID: 10022699
    [Abstract] [Full Text] [Related]

  • 9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.
    BJU Int; 2011 Jun 01; 107(11):1748-54. PubMed ID: 20883488
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant androgen deprivation therapy before radical prostatectomy: who is unlikely to benefit?
    Rabbani F, Sullivan LD, Goldenberg SL, Stothers L.
    Br J Urol; 1997 Feb 01; 79(2):221-5. PubMed ID: 9052474
    [Abstract] [Full Text] [Related]

  • 11. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG, Johnson CF, Klein E, Peabody JO, Coffield S, Soloway M.
    Urology; 1997 Mar 01; 49(3A Suppl):70-3. PubMed ID: 9123740
    [Abstract] [Full Text] [Related]

  • 12. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.
    Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S.
    J Urol; 1996 Sep 01; 156(3):873-7. PubMed ID: 8709351
    [Abstract] [Full Text] [Related]

  • 13. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F, Lorenzo Patiño MJ, Díaz Bermúdez J, Duarte Novo J, Alvarez Castelo L, Chantada Abal V, Sánchez Rodríguez J, González Martín M.
    Arch Esp Urol; 1997 May 01; 50(4):355-63. PubMed ID: 9313044
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA.
    Urology; 2001 Feb 01; 57(2):281-5. PubMed ID: 11182337
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y.
    J Urol; 2003 Aug 01; 170(2 Pt 1):447-50. PubMed ID: 12853796
    [Abstract] [Full Text] [Related]

  • 16. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW, Valicenti RK, Mulholland SG, Hyslop T, Gomella L.
    Urology; 1998 May 01; 51(5):782-7. PubMed ID: 9610592
    [Abstract] [Full Text] [Related]

  • 17. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 May 01; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 18. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL, SEARCH Database Study Group.
    J Urol; 2003 Jun 01; 169(6):2129-35. PubMed ID: 12771734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.